Prognostic impact of serum transthyretin in patients with non-small cell lung cancer.

The identification of novel biomarkers is of great importance for improving the outcome of patients with non-small cell lung cancer (NSCLC). Therefore, the aim of the present study was to determine whether the serum transthyretin (TTR) level could be used as a novel prognostic biomarker for patients with NSCLC. Serum TTR levels, and nutritional and inflammatory parameters were examined prior to treatment in 42 patients with NSCLC.

[A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors].

Currently, anti-PD-1 inhibitors(nivolumab and pembrolizumab)are used for patients with non-small cell lung cancer (NSCLC), although the role of this biomarker is not yet fully characterized. PD-L1 expression in the tumor has been established as a biomarker of the effects of pembrolizumab; however, a number of PD-L1-negative patients have benefited from nivolumab or other immune checkpoint inhibitors, suggesting that there might be additional relevant biomarkers. Notably, tumor mutation burden or tumor infiltrating lymphocytes might be useful biomarkers for these patients; the gut microbiome has received similar attention.

VV-ECMO during subsequent segmentectomy after right pneumonectomy.

Several reports have described subsequent pulmonary surgery after pneumonectomy. We herein report the case of an 82-year-old woman with metachronous multiple lung cancer who had undergone surgery for adenocarcinoma of the right upper lobe 17 years earlier. Completion pneumonectomy had been performed for residual lung adenocarcinoma 11 years before the presentation in question.